CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
232,215
0
1,556
190,106
30,041
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
30,041
Operating Expenses
Research Development
85,902
110,239
162,389
254,440
213,062
Selling General and Administrative
134,807
94,177
71,303
51,597
36,046
Total Operating Expenses
220,709
204,416
233,692
306,037
249,108
Operating Income or Loss
2,233
-204,416
-232,136
-115,931
-219,067
Interest Expense
15,552
9,684
9,552
7,980
33
Total Other Income/Expenses Net
2,227
4,691
3,402
-3,877
-4,838
Income Before Tax
-11,092
-209,409
-238,286
-127,788
-223,938
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-11,990
-209,409
-238,286
-127,788
-223,938
Net Income
-11,990
-209,339
-238,170
-127,337
-223,260
Net Income available to common shareholders
-11,990
-209,339
-238,170
-127,337
-223,260
Reported EPS
Basic
-
-3.22
-4.48
-3.04
-6.01
Diluted
-
-3.22
-4.48
-3.04
-6.01
Weighted average shares outstanding
Basic
-
65,035
53,134
41,912
37,122
Diluted
-
65,035
53,134
41,912
37,122
EBITDA
-
-196,490
-225,336
-116,812
-222,036